Streetbeat News

Regulatory

BTCUSD

Kamala Harris' first public mention of cryptocurrencies on her campaign trail has sparked excitement among crypto enthusiasts. At a Wall Street fundraising event, she expressed support for emerging technologies like digital assets, leading to mixed reactions from industry observers. Bitcoin's price saw a temporary rally following her remarks.

Portfolio Pulse from Aniket Verma

September 23, 2024 | 9:44 am

NVO

Novo Nordisk is under scrutiny by the US Congress over the pricing of its weight loss drugs. This could impact the company's reputation and financial performance.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 9:21 am

SNY

The FDA has approved Sanofi's Sarclisa (Isatuximab) in combination with other drugs as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 8:55 am

SPY

The S&P 500 Index has outperformed Wall Street projections, driven by declining inflation, a resilient economy, and strong corporate profits. The SPDR S&P 500 ETF Trust (SPY), which tracks the index, has gained significantly since October 2022. Analysts predict further upside if the economy avoids a hard landing, with rate cuts expected to boost small-cap and rate-sensitive stocks. However, uncertainty remains due to upcoming elections.

Portfolio Pulse from Shanthi Rexaline

September 23, 2024 | 8:25 am

BHVN

Biohaven Ltd. (NYSE:BHVN) will announce topline data for its Troriluzole Spinocerebellar Ataxia study on September 23, 2024. The study was designed in collaboration with the FDA. A conference call and webcast will be held to discuss the results.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 7:20 am

MNDR

MaNaDr, a telehealth provider, received a Nasdaq notice for not meeting the minimum bid price rule, with a deadline until March 2025 to comply. The company must raise its share price above $1.00 for 10 consecutive days to avoid delisting.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 7:08 am

TEVA

Teva Pharmaceuticals presented data at the ECNP Congress on switching strategies to UZEDY, a long-acting injectable for schizophrenia. The study highlights the importance of personalized treatment plans and provides insights into pharmacokinetic properties when switching from Perseris.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:58 am

IDYA

IDEAYA Biosciences is set to announce interim Phase 2 data for its drug darovasertib in treating uveal melanoma. The announcement will be made via a pre-market press release and an investor webcast on September 23, 2024. The webcast will cover clinical data, regulatory updates, and trial design.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:52 am

IPHA

Innate Pharma has received clearance from the US FDA for its IND application to start a Phase 1 clinical study of IPH4502, a Nectin-4 ADC, for solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:47 am

AZN

Daiichi Sankyo and AstraZeneca's drug, datopotamab deruxtecan, did not achieve statistical significance in overall survival in a breast cancer trial, despite previous success in progression-free survival. The drug is being developed as a potential treatment option for metastatic breast cancer.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:42 am